Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Combined With Lenvatinib and Sintilimab in Advanced HCC
NCT04599790Phase 2Completed
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Oct 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Started Oct 2020; status: completed.
02
Drugs
sintilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04599790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04599790.